Surgical Management of Breast Cancer Liver Metastasis

Amir A Rahnemai-Azar; Luke V Selby; Maryam B Lustberg; Timothy M Pawlik

doi:10.1016/j.soc.2020.09.003

Surgical Management of Breast Cancer Liver Metastasis

Surg Oncol Clin N Am. 2021 Jan;30(1):27-37. doi: 10.1016/j.soc.2020.09.003. Epub 2020 Oct 28.

Authors

Amir A Rahnemai-Azar¹, Luke V Selby², Maryam B Lustberg³, Timothy M Pawlik⁴

Affiliations

¹ Department of Surgery, Division of Surgical Oncology, California University of Science and Medicine, Colton, CA 92324, USA.
² Department of Surgery, Division of Surgical Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA.
³ Department of Medicine, Division of Medical Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA.
⁴ Department of Surgery, Division of Surgical Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA. Electronic address: tim.pawlik@osumc.edu.

PMID: 33220807
DOI: 10.1016/j.soc.2020.09.003

Abstract

Hepatic resection for patients with isolated breast cancer liver metastases (BCLM) is associated with prolonged disease-free interval and better overall survival in highly selected patients. Patients with limited disease who are not candidates for surgery benefit from ablative therapies for isolated breast cancer metastasis in addition to systemic chemotherapy. In the era of modern effective systemic chemotherapy for BCLM, local regional therapies are warranted, yet only in well-selected patients following discussion in a multidisciplinary setting. This article reviews data related to hepatic resection and ablative therapies of BCLM, as well as long-term outcomes of women treated with these approaches.

Keywords: Breast cancer liver metastasis; Liver metastasectomy; Liver resection; Metastatic breast cancer.

Publication types

Review

MeSH terms

Breast Neoplasms* / surgery
Female
Hepatectomy
Humans
Liver Neoplasms* / surgery